- Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc.
1001 Pawtucket Boulevard West
Website
We are leading a global transformation toward fully automated microbial quality control within pharmaceutical manufacturing. Our products safeguard the most complex and critical bioprocessing workflows in the industry, enabling faster, safer, and higher capacity drug production. Through our unique expertise at the intersection of microbiology, robotic systems, and advanced vision algorithms, we are setting the foundation for end-to-end quality control automation to enable the future of advanced pharmaceutical manufacturing.
We are an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Our flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control, or MQC, testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe.
The Growth Direct platform brings the quality control lab to the manufacturing floor, unlocking the power of in-line / at-the-line MQC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that our customers rely on to ensure safe and consistent supply of important healthcare products.
Offering Team
Deal Managers
- J P Morgan Chase
- Morgan Stanley
- Cowen and Company
Lawyers
- Latham & Watkins LLP
Auditors
- PricewaterhouseCoopers LLP
Pre-IPO Investors
Investors
- Google Ventures
- Intel Ventures
- Patricoff Ventures
- Kleiner Perkins
Pre-IPO Holdings(%)
- 30
- 20
- 05
- 18
Deal Highlights
Deal Tracker
Investors
Filing
14 Jul, 2021Offer
15 Jul, 2021Look Ahead
Lock Up Expiry
15 Jan, 2022Earning
Nov 1, 2018IPO Terms
| Offer Price | $20.00 |
| Offer Size | 7M |
